Skip to page content
Back to overview

Jan 21, 2025

Immunologcially multicompatible cellular products

Life Sciences, Oncology

  • Single editing process and better safety profile
  • Escape from NK-mediated recognition
  • Preservation of cellular physiology

Your contact

Dr. M. Charlotte Hemmer

E-Mail:
chemmer@baypat.de
Phone:
+49 (0) 89 5480177 - 29
Reference Number:
B83148

Challenge

Adoptive transfer of T-cells has proven to have tremendous potential for treating cancer, infections and autoimmune disease. However, in order to prevent rejection of transferred T-cells, the polymorpic human leukocyte antigens (HLA) between donor and recipient T-cells need to be matched. This calls for a high degree of personalization. Therefore, the last years have proposed many approaches to generate universal or at least broadly applicable allogeneic donor cells. Generating autologous T cell products is time-, labor- and cost-intensive. One approach to generate universal donor cells is knocking out HLA class I and II through targeting of beta-2-microglobulin and transcription factor CIITA. Although HLA KO abrogates allogeneic T-cell responses, it elicits NK-cell recognition. To avoid this, many genomic alteration are needed, e.g. fusion construct of HLA-E and beta-2-microglobulin, prolonging and complicating the clinical application of these T cells.

Innovation

It was succesfully shown that a reduction of the diversity of HLA molecules by selective editing of HLA class I molecules can be achieved in primary human T cells in a single editing event and results in inhibition of T-cell alloreactivity and NK-cell recognition simultaneously, but also preserves the T-cell graft’s canonical HLA class I expression. In the presence of allogeneic T cells and NK cells, T cells with remaining expression of a single, matched HLA class I allele show improved functionality in vivo in comparison with conventional allogeneic T cells.

Commercial Opportunities

  • Single step editing process with reexpression of defined antigen receptors
  • Escape from NK-cell mediated recognition and inhibition of T-cell alloreactivity
  • Better safety profile by maintaining T-cell graft's canonical HLA class I expression
  • Preservation of cellular physiology as unique advantage

Development Status

TRL Level 3

References

Interested? Get in touch!

Contact a specific team member via the Team section or simply use our contact form for your request.

Privacy settings

This website uses cookies. Cookies improve its usage and help make this website better.
Privacy policy